KUALA LUMPUR, July 29 (Bernama) -- Bursa Malaysia rebounded to close higher on Wednesday on selective buying of defensive stocks after a volatile trading session. IPPFA Sdn Bhd director of investment strategy and country economist Mohd Sedek Jantan said consumer products and services stocks lifted the key index higher, overcoming lingering geopolitical concerns. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) rose 3.08 points to 1,715.56 from yesterday’s close of 1,712.48. The benchmark index, which opened 1.91 points higher at 1,714.39, moved between 1,710.79 and 1,720.59 during the day’s trading. In the broader market, gainers outstripped decliners 550 to 476, while 612 counters were unchanged, 1,129 untraded, and 48 suspended. Turnover rose to 2.96 billion units valued at RM2.48 billion from 2.94 billion units valued at RM2.56 billion on Tuesday.
深圳迈瑞生物医疗电子股份有限公司（Shenzhen Mindray Bio-Medical Electronics Co., Ltd.，SZSE:300760）过去三个月股价上涨6.8%，市场开始关注其背后的财务实力。深入分析其 股本回报率（ROE） 后可以发现，市场或许正是因其稳健基本面而给予溢价。 ROE亮点 ROE：26% （净利润人民币110亿元 ÷ 股东权益人民币440亿元） 意味着公司每投入1元股本即可产生0.26元利润 远高于行业平均 7.6% ，凸显资本运用效率 盈利表现 过去五年净利润累计增长 16% ，而行业整体则下降 3.5% 高ROE结合高于平均水平的利润留存率，支撑持续盈利扩张 分红政策与留存收益 中位派息率约 58% ，仍保留 42% 利润用于再投资 即使派发多数利润，公司依然实现盈利增长 连续六年稳定派息，显示对股东回报的重视 分析师展望 未来三年派息率预计维持在 65% 左右 即便利润留存率有限，ROE预计仍可提升至 31% 盈利增速可能略微放缓，未来能否维持高ROE成为关键 结论 迈瑞医疗凭借 高ROE + 稳定盈利增长 展现出卓越的经营效率。公司在回馈股东与再投资扩张之间保持良好平衡。然而，随着成长速度预期趋缓，持续维持高资本回报率将是未来能否延续优势的决定因素。